

SAFETY DATA SHEET



Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025
Date of first issue: 19.06.2020

SECTION 1. IDENTIFICATION

Product identifier : Atinvicitinib Formulation
Product code : Numelvi
Other means of identification : NUMELVI 31.6 MG TABLETS FOR DOGS (94528)
NUMELVI 21.6 MG TABLETS FOR DOGS (94530)
NUMELVI 7.2 MG TABLETS FOR DOGS (94531)
NUMELVI 4.8 MG TABLETS FOR DOGS (94532)

Manufacturer or supplier's details

Company : MSD
Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification of the substance or mixture in accordance with ABNT NBR 14725 Standard

Not classified as hazardous in accordance with ABNT NBR 14725

GHS label elements in accordance with ABNT NBR 14725 Standard

Not classified as hazardous in accordance with ABNT NBR 14725

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		>= 50 - < 70
atinvicitinib	2169273-59-8		>= 1 - < 5

Atinvicitinib FormulationVersion
3.1Revision Date:
03.11.2025SDS Number:
6047693-00017Date of last issue: 14.04.2025
Date of first issue: 19.06.2020

SECTION 4. FIRST AID MEASURES**Description of necessary first-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Atinvicitinib Formulation

Version 3.1	Revision Date: 03.11.2025	SDS Number: 6047693-00017	Date of last issue: 14.04.2025 Date of first issue: 19.06.2020
----------------	------------------------------	------------------------------	---

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers. Store in accordance with the particular national regulations.

SAFETY DATA SHEET



Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025 Date of first issue: 19.06.2020

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
atinvicitinib	2169273-59-8	TWA	80 ug/m ³ (OEB 3)	Internal
		Wipe limit	800 ug/100cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks

Eye protection : Consider double gloving.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : solid, tablet

Color : off-white

Odor : odorless

SAFETY DATA SHEET



Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025
Date of first issue: 19.06.2020

Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: Not applicable
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: Not applicable
Relative vapor density	: Not applicable
Relative density	: No data available
Density	: 0,2 - 0,9 g/cm ³
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: No data available

Atinvicitinib Formulation

Version 3.1	Revision Date: 03.11.2025	SDS Number: 6047693-00017	Date of last issue: 14.04.2025 Date of first issue: 19.06.2020
----------------	------------------------------	------------------------------	---

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

atinvicitinib:

Acute oral toxicity	:	Assessment: The substance or mixture has no acute oral toxicity LD50 (Rat): > 2.000 mg/kg Assessment: The substance or mixture has no acute oral toxicity
Acute dermal toxicity	:	LD50 Dermal (Rat, male): > 2.000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**atinvicitinib:**

Atinvicitinib Formulation

Version 3.1	Revision Date: 03.11.2025	SDS Number: 6047693-00017	Date of last issue: 14.04.2025 Date of first issue: 19.06.2020
----------------	------------------------------	------------------------------	---

Species : human skin
Method : in vitro skin corrosion test
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**atinvicitinib:**

Species : Bovine cornea
Result : No eye irritation
Method : in vitro eye irritation test
Remarks : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**atinvicitinib:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Dermal
Species : Mouse
Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

atinvicitinib:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Micronucleus test

Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025 Date of first issue: 19.06.2020

Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

atinvicitinib:

Remarks : Not classified due to lack of data.

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

atinvicitinib:

Effects on fertility : Remarks: Not classified due to lack of data.

Effects on fetal development : Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 90
Teratogenicity: NOAEL: 90
Developmental Toxicity: NOAEL F1: 90

SAFETY DATA SHEET



Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025
Date of first issue: 19.06.2020

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
NOAEL : >= 9.000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

atinvicitinib:

Species : Dog, male and female
NOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 6 Months
Number of exposures : Daily

Species : Rat, male and female
NOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Number of exposures : Daily

Species : Rat, male and female
NOAEL : 12 mg/kg
Application Route : Dermal
Exposure time : 3 Months
Number of exposures : Daily

Aspiration toxicity

Not classified based on available information.

Components:

atinvicitinib:

Not applicable

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)) : > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

SAFETY DATA SHEET



Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025 Date of first issue: 19.06.2020

atinvicitinib:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

EC50 (Mysidopsis bahia (opossum shrimp)): > 100 mg/l
Exposure time: 96 h
Method: OPPTS 850.1500
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 100 mg/l
End point: Growth
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC10: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition of activated sludge
Method: OECD Test Guideline 209

EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition of activated sludge
Method: OECD Test Guideline 209

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

Components:

atinvicitinib:

Partition coefficient: n-octanol/water : log Pow: 1,45

SAFETY DATA SHEET



Atinvicitinib Formulation

Version 3.1 Revision Date: 03.11.2025 SDS Number: 6047693-00017 Date of last issue: 14.04.2025
Date of first issue: 19.06.2020

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

CA. DSL : not determined

AICS : not determined

IECSC : not determined

Atinvicitinib Formulation

Version 3.1	Revision Date: 03.11.2025	SDS Number: 6047693-00017	Date of last issue: 14.04.2025 Date of first issue: 19.06.2020
----------------	------------------------------	------------------------------	---

SECTION 16. OTHER INFORMATION

Revision Date : 03.11.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided

SAFETY DATA SHEET



Atinvicitinib Formulation

Version
3.1

Revision Date:
03.11.2025

SDS Number:
6047693-00017

Date of last issue: 14.04.2025
Date of first issue: 19.06.2020

relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8